Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality

被引:397
作者
Aran, Veronica [1 ]
Victorino, Ana Paula [1 ]
Thuler, Luiz Claudio [2 ]
Ferreira, Carlos Gil [1 ,3 ]
机构
[1] Brazilian Natl Canc Inst INCA, Div Clin Res, Rua Andre Cavalcanti 37, BR-20231050 Rio De Janeiro, Brazil
[2] Brazilian Natl Canc Inst INCA, Clin Epidemiol Program, Rio De Janeiro, Brazil
[3] Natl Clin Canc Res Network RNPCC SCTIE MS, Rio De Janeiro, Brazil
关键词
Colorectal cancer incidence; Genetics; Prevention; Risk factors; Treatment; KIRSTEN RAS MUTATIONS; III COLON-CANCER; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; CIGARETTE-SMOKING; SERRATED PATHWAY; PHASE-III; ADJUVANT CHEMOTHERAPY; ALCOHOL METABOLISM; RISK-FACTORS;
D O I
10.1016/j.clcc.2016.02.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Colorectal cancer (CRC) is a multifactorial disease resulting from lifestyle, genetic, and environmental factors. There are hereditary and non-hereditary CRC types; however, the majority are non-hereditary and mainly caused by somatic mutations in response to environmental factors. In past years, researchers have focused their attention on the mechanisms behind these factors and the methods of improving disease prevention and treatment. Improving the awareness of the population with regard to the benefits of a healthy lifestyle, including a balanced diet associated with exercise, could globally reduce CRC risk. The present review aims to address the current knowledge on CRC, taking into consideration the common molecular alterations upon different environmental and non-environmental factors, current and promising treatment interventions, and how all these factors may interact to positively or negatively influence CRC risk.
引用
收藏
页码:195 / 203
页数:9
相关论文
共 125 条
[1]
Aalok Kumar HFK, 2012, J CLIN ONCOL S, V30
[2]
Al-Mulla F, 1999, J PATHOL, V187, P433, DOI 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO
[3]
2-E
[4]
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial [J].
Alberts, Steven R. ;
Sargent, Daniel J. ;
Nair, Suresh ;
Mahoney, Michelle R. ;
Mooney, Margaret ;
Thibodeau, Stephen N. ;
Smyrk, Thomas C. ;
Sinicrope, Frank A. ;
Chan, Emily ;
Gill, Sharlene ;
Kahlenberg, Morton S. ;
Shields, Anthony F. ;
Quesenberry, James T. ;
Webb, Thomas A. ;
Farr, Gist H., Jr. ;
Pockaj, Barbara A. ;
Grothey, Axel ;
Goldberg, Richard M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13) :1383-1393
[5]
Processed meat and colorectal cancer: a quantitative review of prospective epidemiologic studies [J].
Alexander, Dominik D. ;
Miller, Arthur J. ;
Cushing, Colleen A. ;
Lowe, Kimberly A. .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2010, 19 (05) :328-341
[6]
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].
Allegra, Carmen J. ;
Jessup, J. Milburn ;
Somerfield, Mark R. ;
Hamilton, Stanley R. ;
Hammond, Elizabeth H. ;
Hayes, Daniel F. ;
McAllister, Pamela K. ;
Morton, Roscoe F. ;
Schilsky, Richard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096
[7]
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[8]
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[9]
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[10]
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684